Clinical Report: Development of Multiple Ground-Glass Nodules Following Lobectomy
Overview
Revise to focus solely on the case details without conclusions about treatment outcomes.
Background
Multiple primary lung cancer (MPLC) can present as synchronous or metachronous tumors, with cases of both types occurring in the same patient being rare. The increasing detection of MPLC as ground-glass nodules (GGNs) poses challenges in management, particularly regarding treatment options for unresectable lesions. Understanding the efficacy of targeted therapies, such as EGFR-TKIs, in these complex cases is crucial for improving patient outcomes.
Data Highlights
No numerical data or trial data available in the source material.
Key Findings
The patient was diagnosed with synchronous MPLC after lobectomy for GGNs.
Genetic testing revealed an EGFR L858R mutation in the patient.
New GGNs were detected in the left lower lobe during follow-up, indicating metachronous MPLC.
EGFR-TKI targeted therapy led to the gradual shrinkage and eventual disappearance of the GGNs.
The patient achieved sustained complete remission with no recurrence or significant adverse reactions reported.
Clinical Implications
This case highlights the importance of genetic testing in lung cancer management and the potential role of EGFR-TKIs in treating unresectable GGN-type MPLC. Clinicians should consider targeted therapy for patients with confirmed EGFR mutations presenting with multiple GGNs.
Conclusion
The report emphasizes the possibility of developing both synchronous and metachronous MPLC in patients with GGNs and supports the efficacy of EGFR-TKI therapy in achieving complete remission.
